Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

Generated Narrative: Evidence 236987

version: 64; Last updated: 2024-12-14 08:46:28+0000

Profile: ComparativeEvidence

url: https://fevir.net/resources/Evidence/236987

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236987, outcomeId/109588, picoId/85798, sectionId/73215

name: Body_weight_from_MAGICapp_109588

title: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationComparativeEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

RelatedArtifacts

-TypeResourceReference
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

assertion:

SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.

variableDefinition

description:

Adults with type 2 diabetes

variableRole: Population

observed: Adults with type 2 diabetes and CVD and CKD

variableDefinition

description:

GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableRole: Exposure

comparatorCategory: GLP-1 RA

observed: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableDefinition

description:

Body weight

variableRole: Outcome

observed: Body weight

synthesisType: SYSTEMATIC_REVIEW

studyDesign: NOTSET

statistic

description:

MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)

statisticType: Mean Difference

quantity: -0.47 Kg

SampleSizes

-NumberOfStudiesNumberOfParticipants
*21139

AttributeEstimates

-TypeRange
*CI95-0.09--0.85 Kg

certainty

description:

Due to serious inconsistency

type: Overall certainty

rating: Moderate certainty

Subcomponents

-TypeRating
*Risk of BiasNOTSET
*InconsistencySERIOUS
*IndirectnessNOTSET
*ImprecisionNOTSET
*Publication BiasNOTSET